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Identification and characterization of leukemia-initiating cells (LICs) is important to understand leukemogen-
esis and develop novel therapies for leukemia. In this issue of Cell Stem Cell, Gibbs et al. (2012) demonstrate
that common active signaling pathways in LICs may be targeted to treat acute myeloid leukemia.Previous studies have demonstrated
that CD34+CD38 hematopoietic cells,
but not the more mature CD34+CD38+
progenitors, could generate leukemia in
immunocompromised NOD/SCID mice
(Bonnet and Dick, 1997). This observation
supported the notion that leukemia was
initiated and maintained in vivo by a small
fraction of leukemia stem cells, or
leukemia-initiating cells (LICs), derived
from hematopoietic stem cells (HSCs). In
recent years, several laboratories have
shown that even other less primitive
fractions of hematopoietic cells, for exam-
ple CD34+CD38+ cells, can generate
leukemia in more immunocompromised
NSG mice, supporting the notion that
LICs can also arise from hematopoietic
progenitors (Bonnet and Dick, 1997;
Dick, 2009).
In the current issue of Cell Stem Cell,
Gibbs et al. (2012) use a mouse model
for acute myeloid leukemia (AML) engi-
neered by overexpression of HoxA9
and Meis1 homeobox genes important
for self-renewal (Kroon et al., 1998).
To identify the LICs by immunopheno-
type, the authors purified hematopoietic
stem/progenitor cells, which express
c-kit (Linkit+), kit+ cells coexpressing
lymphoid markers (Lym+kit+) or myeloid
markers (Gr1+kit+), and mature myeloid
cells (Gr1+kitlo) from HoxA9-Meis1 (H9M)
mice. These purified fractions were then
transplanted into irradiated wild-type
mice to determine their tumorigenicity.
All transplanted cell fractions generated
leukemia in the recipients except the
Gr1+kitlo cells. These findings show that
the LICs represent malignant hemato-
poietic progenitors that are immuno-
phenotypically heterogeneous. Further-
more, each immunophenotype of LIC
from primary leukemias could recapitu-late all the LIC immunophenotypes in
secondary recipients. In rigorous experi-
ments, the authors plated single Lym+kit+
and Gr1+kit+ leukemic cells from primary
recipients into clonal liquid cultures and
transplanted single colonies from these
cultures into irradiated recipients. Inter-
estingly, single colonies derived from
different immunophenotypic LICs gener-
ated all three LIC immunophenotypes.
Since the mature myeloid cells (Gr1+kitlo)
do not generate leukemia, LICs comprise
a distinct lineage hierarchy. However,
since the Lym+kit+ and Gr1+kit+ cells
could generate Linkit+ LIC, the hier-
archy is atypical (see Figure 1).
Because the three distinct LIC popula-
tions seemed to share developmental
lineage potential, the authors hypothe-
sized that they may possess common
cell signaling and genetic properties. To
characterize the genetic signatures of
these three different immunophenotypic
LICs, the authors analyzed and compared
microarray data from each LIC popula-
tion. The genetic signatures were found
to be very similar between all three LICs.
Furthermore, mass cytometry was used
to analyze intracellular signaling in each
LIC following cytokine stimulation, and
the findings demonstrated that all three
distinct LICs have largely conserved
signaling networks. They exhibited activa-
tion of MAP kinase, DNA methyltransfer-
ase, receptor tyrosine kinases, and
PI3K/Akt. Inhibitors against two of these
signaling pathways were tested in vivo
and shown to prolong survival. These
findings demonstrate that immunopheno-
typic analysis to identify LICs may have to
be complemented by molecular analysis
to identify epigenetic regulators and
signal transduction pathways that are
altered and shared across LICs.Cell Stem Cell 10In human leukemias, it has also been
difficult to find exact immunophenotypic
markers that characterize all LICs. For
example, two recent studies found that
LICs represented hematopoietic progeni-
tors with several different immunopheno-
types (Goardon et al., 2011; Sarry et al.,
2011). Goardon et al. (2011) examined
a large group of primary AML patients
and found two different progenitor-like
LICs: one multipotent population and
another representing granulocyte-macro-
phage progenitors (GMPs). Their relation-
ship was hierarchical because the multi-
potent population could generate the
GMP-like LICs, but not the other way
around. These findings are analogous to
those in the present paper, with the
exception that no strict hierarchical rela-
tionship was found between the different
LIC populations in murine AML. It is inter-
esting that in humans, different AML
subtypes harboring disparate genetic
mutations are similarly defined by only
two populations of LICs with different im-
munophenotypes. Another recent study
also reported progenitor-like LICs in
primary AML with different immunophe-
notypes, some without expression of
lineage markers (LinCD38) and others
expressing lineage markers CD38 or
CD45RA (Sarry et al., 2011). Interestingly,
the different immunophenotypic LICs
could generate each other in vivo, similar
to murine LICs in the present paper by
Gibbs et al. (2012).
From the above findings, it is clear that
identifying LICs based on one defined
immunophenotype can be a challenge.
First, there are many different leukemias
with different histological subtypes
caused by different genetic mutations.
The AML studied by Gibbs et al. is more
homogenous than the human leukemias, February 3, 2012 ª2012 Elsevier Inc. 109
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Figure 1. Different Models for Leukemia-Initiating Cells
(A) A classical hierarchical model: Leukemia-initiating ability is restricted to a small fraction of hematopoi-
etic-stem-cell-like cells, defined by a particular immunophenotype, that generate progeny cells that lack
tumor-initiating ability. (B) An atypical hierarchical model: Various types of hematopoietic-stem-cell-like or
progenitor-like cells comprise leukemia-initiating cells (LICs), and these cells can independently generate
other LICs with distinct immunophenotypes and therefore exhibit an atypical hierarchy. Hence it is not
possible to identify LICs with a single immunophenotype (as shown in Gibbs et al., 2012). (C) A signaling
network model: LICs with different immunophenotypes exhibit activation of common signaling pathways
(as shown in Gibbs et al., 2012). Therefore, characterization of intrinsic signaling networks as well as
immunophenotypic analysis will be needed for more effective identification of LICs. Please note that
the models in (B) and (C) are not mutually exclusive. Cell bodies in blue are LICs, while the orange cells
do not have leukemia-initiating activity.
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sion of HoxA9-Meis1, is the same in all
animals. Despite this, the authors find
LICs with three different immunopheno-
types. However, it is also possible that
the authors did not find an immunopheno-
type that may be common to all LICs. The
present findings and previously published
papers report clearly that LICs are not
restricted to HSCs, but can also be
progenitor-like, provided that the LIC
progenitors can undergo effective self-
renewal. Expression profile analysis of
LICs demonstrates that they have active
self-renewal gene signatures, an impor-
tant definition of LICs. The findings in
Gibbs et al. (2012) present a novel and
more functional definition of LICs, where
common genetic and signal transduction
pathways may characterize LICs better
than the cell surface characteristics or110 Cell Stem Cell 10, February 3, 2012 ª201immunophenotype. While cell surface
characteristics may not define LICs,
recent studies have identified several
cell surface markers that predict the
ability of LICs to grow and metastasize.
For example, antibodies against CD44 ex-
pressed on LICs could markedly deplete
human LIC engrafted in NOD/SCID mice.
Similarly, in HOXA10-Meis1 induced
murine leukemia, prevention of secondary
leukemias was achieved upon treatment
of the recipients with antibodies against
CD44 (Jin et al., 2006; Que´re´ et al.,
2011). In the latter study, the expression
of the CD44 gene was unaltered.
However, increased protein levels of
CD44 were discovered by screening the
LICs by proteomics, indicating that ex-
pression profile analysis may not always
be sufficient to find key molecules that
are dysregulated in LICs (Que´re´ et al.,2 Elsevier Inc.2011). Therefore, in developing better
therapies, it will be essential to determine
the immunophenotypes that enable LICs
to sustain growth of leukemic cells.
However, as the findings of Gibbs et al.
(2012) emphasize, in addition to immuno-
phenotypes, LICs also have to be better
characterized with regard to their func-
tional properties. What cell surface mole-
cules, signal transduction pathways, and
epigenetic regulators allow these cells to
self-renew and metastasize throughout
the body, and how can we effectively
target or block these pathways? The
paper by Gibbs et al. (2012) has uncov-
ered the first steps needed to answer
these questions.REFERENCES
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